Replies to post #33962 on Lifeline Biotechnologies Inc (LLBO)

[GetSeriousOK]

NO because there is nothing called the iTbra any more. It is not called the Cyrcadia Breast Monitor (CBM). "iTBra" was coined for the Cisco partnership because Cisco wass promoting their "Internet of Everything" (IOE) campaign, but Cisco stopped working with Cyrcadia.

The CBM might be a "true product" and it might not. It's in development and has been since the 1980's. It's not cleared by the US FDA or the Chinese FDA and likely never will be, because:

1. the US clinical trials, started in 2015, were supposed to be finished in six months. SIX YEARS LATER, they aren't even half completed. There's no rational reason to believe they will ever be completed.

2. Cyrcadia Inc in the USA is dormant. They haven't release a PR in years. the company is run by James Holmes and we all know what a business genius James Holmes is by the way he lost LLBO to Acropolis.

3. Cyrcadia Asia is doing nothing other than panhandling for funds. Galen Growth is not a health conference or a health symposium -- it's a bunch of startups asking for funding.

In conclusion, the CBM (formerly known as the iTBra) has very little to do with LLBO's value. If and when LLBO gets Pink Current and if and when some private company buys it for a reverse merger, the resulting company won't be promoting, developing, or marketing the CBM. The resulting company will own some restricted common stock in Cyrcadia that might actually be worth $$$0 depending on what the restrictions are.

But my original statement (assuming we want to stay on subject here) was that compared to KAST, LLBO is UGLY (as is KATX). This is true because of the share structure and the debt.

KATX O/S and A/S are 1.76 billion out of 2 billion, requiring a reverse split almost immediately to allow the resulting company to sell some new stock. They also have $1,915,000 in unpaid debt.

LLBO O/S and A/S are 3.35 billion out of 4.6 billion. The resulting company might not do a R/S immediately, but they would certainly think about it. LLBO also has $390,000 in unpaid debt.

KAST O/S and A/S are 62.5 million out of 950 million. The resulting company won't need to do a R/S at all. They only have $24,605 in debt.

KAST is a gem when compared to KATX and LLBO. If Acropolis can't sell KAST, I don't see any rational reason to believe Acropolis will be able to sell KATX or LLBO.